Australia markets closed

Stoke Therapeutics, Inc. (STOK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.50-0.67 (-4.73%)
At close: 04:00PM EDT
12.90 -0.60 (-4.45%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close14.17
Open14.19
Bid10.21 x 200
Ask13.51 x 200
Day's range12.20 - 14.25
52-week range3.35 - 16.40
Volume4,557,479
Avg. volume941,903
Market cap619.896M
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

    BEDFORD, Mass., March 28, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730

  • Business Wire

    Stoke Therapeutics Announces Proposed Public Offering

    BEDFORD, Mass., March 26, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock. In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an addi

  • Business Wire

    Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

    BEDFORD, Mass., March 25, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2023.